In this webinar, Dr. Ilan Rabiner provided insight on Molecular and functional imaging and how it has become an indispensable component of early phase drug development. The appropriate use of these techniques provides information on the three pillars of drug survival and provides early risk reduction in the development portfolio.
Ilan is a psychiatrist and psychopharmacologist who was part of the team that set up the GlaxoSmithKline Clinical Imaging Centre, which transitioned to become Imanova in Sep 2011. Ilan spent 10 years at GlaxoSmithKline, and was head of Clinical Imaging Applications at the Translational Medicine and Technologies group.
Ilan received a BSc in Physiology and Medical Biochemistry and a MBBCh, from the University of the Witwatersrand, and specialist training in psychiatry at the University of Cape Town. He was trained in molecular imaging at the MRC Cyclotron Unit, Hammersmith Hospital, London.
Ilan’s research interests focus on the application of molecular imaging to human pathophysiology, psychopharmacology and central nervous system drug development. He is an author of >140 peer reviewed publications.